Practical Guidance for Pharmaceutical Method-of-Use Patent Claims After Teva v. Eli Lilly and In re Xencor National Law Review 17:25 Mon, 20 Jul
Xencor Announces Proffered Paper Oral Presentation at Esmo 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Business Wire (Press Release) 14:12 Fri, 17 Jul
Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus National Law Review 21:41 Wed, 15 Jul
